Literature DB >> 7408390

Atenolol kinetics in renal failure.

J McAinsh, B F Holmes, S Smith, D Hood, D Warren.   

Abstract

Blood and urine levels of atenolol were measured in 12 subjects--2 anephric and 10 with creatinine clearances ranging from 0 to 122 ml/min/1.73 m2. In a single-dose study subjects were given atenolol 100 mg by mouth, and blood and urine levels were measured during the subsequent 72 hr. In a repeated-dose study 10 subjects were given atenolol 100 mg for 20 days, and blood and urine levels were measured before and for 72 hr after the final dose on day 21. In the single-dose study the peak blood level occurred later and the 24-hr plasma concentrations increased as creatinine clearance decreased. The range in peak blood level was sixfold throughout this range of creatinine clearance. The blood atenolol half-life (t1/2) increased from about 6 hr to more than 100 hr with progressive renal failure and there was a corresponding decrease in elimination rate constant and increase in area under the curve. In the repeated-dose study there was good correlation between predose blood level of atenolol and both logarithm creatinine clearance and serum creatinine, and the elimination rate constant correlated with creatinine clearance and the logarithm of serum creatinine. In the single-dose study minimum heart rates were observed just after the peak atenolol level. Blood pressure response did not correlate closely with serum atenolol levels. Dosing recommendations are suggested for patients with renal failure to take account of the effects of renal function on atenolol kinetics.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7408390     DOI: 10.1038/clpt.1980.166

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

Review 1.  Old antihypertensive agents-diuretics and beta-blockers: do we know how and in whom they lower blood pressure?

Authors:  D A Sica
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 2.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

3.  Prescription monitoring of drug dosages in the county of Jämtland and Sweden as a whole in 1976, 1982 and 1985.

Authors:  A Wessling; G Boëthius; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis.

Authors:  A Celardo; G L Traina; M Arboix; A Puigdemont; M Bonati
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

Review 5.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

6.  β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.

Authors:  Alvin Tieu; Thomas J Velenosi; Andrew S Kucey; Matthew A Weir; Bradley L Urquhart
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-08       Impact factor: 8.237

7.  The effect of ageing on the disposition of nifedipine and atenolol.

Authors:  M Scott; C M Castleden; H K Adam; R P Smith; T J Fitzsimons
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

8.  Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.

Authors:  A K Salahudeen; R Wilkinson; J McAinsh; D N Bateman
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of atenolol--a review.

Authors:  W Kirch; K G Görg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982       Impact factor: 2.441

10.  Interaction between the beta-adrenoceptor blockers metoprolol and atenolol with amitriptyline and their effects on oxidative liver metabolism.

Authors:  W Kirch; H Spahn; N R Kitteringham; H J Hutt; E Mutschler; E E Ohnhaus
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.